Ikena Oncology, Inc. – NASDAQ:IKNA

Add to watchlist

$1.46

-0.08

-5.19%

Market closed

Open in 2 days

-9.41%

month

-9.41%

quarter

-26.67%

year

Market Cap	86.86M
Enterprise value	120.20M

P/E	-2.21
EV/Sales	7.69
EV/EBITDA	-1.82
Price/Sales	11.16
Price/Book	1.18
PEG ratio	0.03
EPS	-1.58

Revenue	N/A
EBITDA	-76.16M
Income	-70.09M
Revenue Q/Q	-100%
Revenue Y/Y	-78.07%

Profit margin	-440.29%
Oper. margin	-453.98%
Gross margin	0%
EBIT margin	-453.98%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Ikena Oncology, Inc. (NASDAQ:IKNA): Profit margin
Jun 2023	2.00M	-17.11M	-854.04%
Sep 2023	1.18M	-17.34M	-1463.54%
Dec 2023	659K	-19.48M	-2957.36%
Mar 2024	0	-16.14M

Ikena Oncology Financials Estimate

Q Y

Ikena Oncology, Inc. (NASDAQ:IKNA): Analyst Estimates
Sep 2025	591.11K	-14.47M	-2449.33%
Oct 2025	0	-9.41M
Dec 2025	0	-9.65M
Mar 2026	573.03K	-13.10M	-2287.58%

Analysts Price target
Financials & Ratios estimates

Ikena Oncology, Inc. (NASDAQ:IKNA): Debt to assets
Jun 2023	171764000	15.06M	8.77%
Sep 2023	215335000	59.99M	27.86%
Dec 2023	192092000	22.33M	11.63%
Mar 2024	172782000	17.43M	10.09%

Ikena Oncology, Inc. (NASDAQ:IKNA): Cash Flow
Jun 2023	-18.14M	22.68M	37.00M
Sep 2023	-19.99M	31.89M	38.91M
Dec 2023	-21.81M	20.37M	60K
Mar 2024	-18.30M	-48.73M	0

Ikena Oncology alternative data

Ikena Oncology, Inc. (NASDAQ:IKNA): Employee count
Aug 2023	74
Sep 2023	59
Oct 2023	59
Nov 2023	59
Dec 2023	57
Jan 2024	57
Feb 2024	57
Mar 2024	43
Apr 2024	43
May 2024	43
Jun 2024	34
Jul 2024	34

Ikena Oncology
Hedge Funds Holdings Q1 2023

19.87% -52.57%

of IKNA is owned by hedge funds

18 -15

hedge funds hold IKNA stock

7.19M -19.07M

shares is hold by hedge funds

IKNA hedge funds holdings changes

Ikena Oncology
Insider Trading

Ikena Oncology, Inc. (NASDAQ:IKNA): Insider trades (number of shares)
Period	Buy	Sel
Dec 2021	0	53556
Jan 2022	0	1000
Jun 2022	504450	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	24 Jun 2022	ORBIMED ADVISORS LLC director director	Common Stock	96,035	$5.37	$515,708
Purchase	24 Jun 2022	ORBIMED ADVISORS LLC director director	Common Stock	65,965	$4.37	$288,267
Purchase	24 Jun 2022	BONITA DAVID P director director	Common Stock	96,035	$5.37	$515,708
Purchase	24 Jun 2022	BONITA DAVID P director director	Common Stock	65,965	$4.37	$288,267
Purchase	23 Jun 2022	ORBIMED ADVISORS LLC director director	Common Stock	23,419	$3.71	$86,884
Purchase	23 Jun 2022	BONITA DAVID P director director	Common Stock	23,419	$3.71	$86,884
Purchase	22 Jun 2022	ORBIMED ADVISORS LLC director director	Common Stock	66,806	$3.55	$237,161
Purchase	22 Jun 2022	BONITA DAVID P director director	Common Stock	66,806	$3.55	$237,161
Option	18 Jan 2022	TESSIER MAUDE officer: Chief Business Officer officer: Chief Business Officer	Stock Option (Right to Buy)	71,786	$3.87	$277,596
Option	18 Jan 2022	TESSIER MAUDE officer: Chief Business Officer officer: Chief Business Officer	Common Stock	71,786	$3.87	$277,596

IKNA insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application TEAD INHIBITORS AND USES THEREOF Filling date: 3 Jan 2022 Issue date: 11 Aug 2022	3 Jan 2022	11 Aug 2022
Grant	Grant Utility: Indole AHR inhibitors and uses thereof Filling date: 8 Apr 2020 Issue date: 14 Jun 2022	8 Apr 2020	14 Jun 2022
Application	Application INDOLE AHR INHIBITORS AND USES THEREOF Filling date: 16 Oct 2019 Issue date: 12 May 2022	16 Oct 2019	12 May 2022
Grant	Grant Utility: Tead inhibitors and uses thereof Filling date: 29 May 2020 Issue date: 15 Mar 2022	29 May 2020	15 Mar 2022
Application	Application ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF Filling date: 18 Dec 2020 Issue date: 30 Sep 2021	18 Dec 2020	30 Sep 2021
Application	Application POLYMORPHIC COMPOUNDS AND USES THEREOF Filling date: 25 Nov 2020 Issue date: 19 Aug 2021	25 Nov 2020	19 Aug 2021
Application	Application ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF Filling date: 18 Dec 2020 Issue date: 29 Jul 2021	18 Dec 2020	29 Jul 2021
Application	Application PEGYLATED KYNURENINASE ENZYMES AND USES THEREOF FOR THE TREATMENT OF CANCER Filling date: 16 Oct 2020 Issue date: 22 Apr 2021	16 Oct 2020	22 Apr 2021
Application	Application AHR INHIBITORS AND USES THEREOF Filling date: 2 Jun 2020 Issue date: 21 Jan 2021	2 Jun 2020	21 Jan 2021
Application	Application TEAD INHIBITORS AND USES THEREOF Filling date: 29 May 2020 Issue date: 31 Dec 2020	29 May 2020	31 Dec 2020

Ikena Oncology
Executives

Insider	Age	Compensation
Dr. Mark Manfredi Ph.D. (1971) Pres. Chief Executive Officer & Director	54	$606,060
Mr. Douglas R. Carlson (1979) Chief Operating Officer & Executive Vice President of Fin.	46	$469,130
Dr. Sergio L. Santillana M.B.A., M.D., M.Sc., MSc (1963) Chief Medical Officer	62	$377,770

Ikena Oncology
Latest News

Monday, 23 December 2024
08:37	Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement	globenewswire.com
08:30	Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement	globenewswire.com
Thursday, 7 November 2024
08:30	Ikena Oncology Reports Third Quarter 2024 Financial Results	globenewswire.com
Thursday, 8 August 2024
16:15	Ikena Oncology Reports Second Quarter 2024 Financial Results	globenewswire.com
Friday, 12 July 2024
11:15	Best Momentum Stocks to Buy for July 12th	zacks.com
07:40	New Strong Buy Stocks for July 12th	zacks.com
Tuesday, 28 May 2024
16:42	UPDATE – Ikena Oncology Announces Strategic Update	globenewswire.com
16:15	Ikena Oncology Announces Strategic Update	globenewswire.com
Monday, 13 May 2024
16:45	Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update	globenewswire.com
Wednesday, 10 April 2024
08:00	Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum	GlobeNewsWire
Wednesday, 24 January 2024
10:36	Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround	Zacks Investment Research
Tuesday, 20 June 2023
10:16	Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why	Zacks Investment Research
Friday, 2 June 2023
09:53	Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why	Zacks Investment Research
Wednesday, 24 May 2023
08:00	Ikena Oncology to Participate in Upcoming Investor Conferences	GlobeNewsWire
Monday, 15 May 2023
10:41	Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Friday, 5 May 2023
03:50	Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?	Zacks Investment Research
Tuesday, 14 March 2023
09:58	Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates	Zacks Investment Research
Monday, 7 November 2022
11:30	Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates	Zacks Investment Research
Wednesday, 5 October 2022
08:05	Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting	GlobeNewsWire
Wednesday, 18 May 2022
07:00	Ikena Oncology to Participate in Spring 2022 Investor Conferences	GlobeNewsWire
Thursday, 12 May 2022
09:47	Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Wednesday, 11 May 2022
09:47	Is a Surprise Coming for Ikena Oncology (IKNA) This Earnings Season?	Zacks Investment Research
09:02	5 Biotech Stocks Set to Outpace Q1 Earnings Estimates	Zacks Investment Research
Thursday, 28 April 2022
07:00	Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting	GlobeNewsWire
Monday, 7 March 2022
16:30	Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting	GlobeNewsWire
Thursday, 7 October 2021
09:00	Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment	GlobeNewsWire
Friday, 1 October 2021
08:15	Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting	GlobeNewsWire
Thursday, 2 September 2021
07:00	Ikena Oncology to Participate in September 2021 Virtual Investor Conferences	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 28 Mar 2021

US IPO Weekly Recap: Healthcare Shines In A 17 IPO Week

Frequently Asked Questions (FAQ)

What's the price of Ikena Oncology stock today?

One share of Ikena Oncology stock can currently be purchased for approximately $1.46.
When is Ikena Oncology's next earnings date?

Unfortunately, Ikena Oncology's (IKNA) next earnings date is currently unknown.
Does Ikena Oncology pay dividends?

No, Ikena Oncology does not pay dividends.
How much money does Ikena Oncology make?

Ikena Oncology has a market capitalization of 86.86M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 41.35% to 9.16M US dollars.
What is Ikena Oncology's stock symbol?

Ikena Oncology, Inc. is traded on the NASDAQ under the ticker symbol "IKNA".
What is Ikena Oncology's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Ikena Oncology?

Shares of Ikena Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Ikena Oncology's key executives?
Ikena Oncology's management team includes the following people:
- Dr. Mark Manfredi Ph.D. Pres. Chief Executive Officer & Director(age: 54, pay: $606,060)
- Mr. Douglas R. Carlson Chief Operating Officer & Executive Vice President of Fin.(age: 46, pay: $469,130)
- Dr. Sergio L. Santillana M.B.A., M.D., M.Sc., MSc Chief Medical Officer(age: 62, pay: $377,770)
How many employees does Ikena Oncology have?

As Jul 2024, Ikena Oncology employs 34 workers, which is 21% less then previous quarter.
When Ikena Oncology went public?

Ikena Oncology, Inc. is publicly traded company for more then 4 years since IPO on 26 Mar 2021.
What is Ikena Oncology's official website?

The official website for Ikena Oncology is ikenaoncology.com.
Where are Ikena Oncology's headquarters?

Ikena Oncology is headquartered at 645 Summer Street, Boston, MA.
How can i contact Ikena Oncology?

Ikena Oncology's mailing address is 645 Summer Street, Boston, MA and company can be reached via phone at 857 273 8343.

Ikena Oncology, Inc.

ikenaoncology.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

857 273 8343

645 Summer Street
Boston, MA 02210

CIK: 0001835579
ISIN: US45175G1085
CUSIP: 45175G108